肺癌基因分子靶向标志监测.pptVIP

ERCC1-SNP位点的基因表达结果图 ERCC2SNP:118A/C杂合型 ERCC2SNP:1009A/G杂合型 Abstract No: 7514 R. Rosell, Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies. Conclusions: The high frequency of pretreatment double mutations concurs with a previous report (Mah eswaran et al. NEJM 2008). The strong influence of T790M and BRCA1 levels on erlotinib outcome can lead to novel personalized treatment strategies. Abstract No: 7615 131 patients with stage IIIB (wet) and IV NSCLC. qRT-PCR was used to analyze the tumoral expression Results: The mRNA levels of TXR1-TSP1 were inversely correlated (Spearmans test: -0.37; p = 0.001). Low TXR1 mRNA levels were associated with higher response rate (RR; p = 0.018), longer median progression free survival (PFS; p = 0.029) and median overall survival (mOS p = 0.003), while high TSP1 expression was also, correlated with higher RR (p = 0.035), longer PFS (p 0.0001) and mOS (p 0.0001). In addition, patients whose primary tumors presented higher BRCA1 mRNA expression experienced higher RR (p = 0.028) and increased PFS (p = 0.021), but not mOS (p = 0.4) in comparison with those with low BRCA1 tumoral expression. chemotherapy resistance in patients with advanced/metastatic non-small cell lung cancer ---C. Papadaki. Abstract No: e18051 C. Zhou; The relationship of EGFR intron 1 (CA) and microsatellite polymorphism and the efficacy of EGFR-TKI in advanced NSCLC patients 70 patients sequenced in an ABI3100 Conclusions: EGFR (CA)n repeats may be another biomarker to predict the effect of EGFR-TKI, patients with a low number of EGF receptor CA repeats (any allele ≤ 17 CA) are more likely to have a better clinical outcome than patients with a high number of CA repeats (both alleles 17 CA) during targeted therapy with EGFR-TKI. benefited more from anti-tubulin containing regimen platinum-containing regimen gemcitabine- contain